Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients

Abstract

The presence of atherogenic dyslipidemia was associated with higher residual cardiovascular risk in PERFORM and SPARCL subjects with stroke or transient ischemic attack receiving statin therapy. Specific therapeutic interventions should now be trialed to address this residual risk.